Fig. 6: The change in the research focus of drug modalities over time.
From: Dynamic clinical trial success rates for drugs in the 21st century
a Shifts in the research focuses of drug modalities measured by the numbers of clinically tested unique molecular entities. Percentage of small molecular drugs had been declining from 66.3% (the start of the 21st century) to 46.6% (now) with observable increase of the shares of antibody-related drugs (from 10.8% to 19.5%) and other drugs (from 13.5% to 25.8%). b The shifts in research focus of drug modalities measured by the total numbers of CDPs. The percentages of CDPs of small molecular drugs kept declining from 72.4% to 57.2% with a clear increase of the share of antibody-related drugs (from 11.1% to 21.4%) and others (from 6.7% to 12.8%). CDPs clinical development programs.
